Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.71 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.71 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113212 | 0.91 | CYP4F2 (0.76) | CYP4F2CYP4A11HSP90AB1ALDH1A1GAA | |
| SCHEMBL29963675 | 0.83 | CYP4F2 (0.67) | CYP4F2CYP4A11HSP90AB1ALDH1A1GAA | |
| SCHEMBL9332759 | 0.83 | CYP4A11 (1.00) | CYP4F2CYP4A11HSP90AB1ALDH1A1GAA | |
| SCHEMBL1107142 | 0.83 | CYP4F2 (0.66) | CYP4F2CYP4A11HSP90AB1ALDH1A1GAA | |
| SCHEMBL112488 | 0.83 | CYP4F2 (0.66) | CYP4F2CYP4A11HSP90AB1ALDH1A1GAA | |
| SCHEMBL7981410 | 0.83 | CYP4F2 (0.66) | CYP4F2CYP4A11HSP90AB1ALDH1A1GAA | |
| SCHEMBL4613929 | 0.83 | CYP4F2 (0.66) | CYP4F2CYP4A11HSP90AB1ALDH1A1GAA | |
| SCHEMBL4104271 | 0.83 | CYP4F2 (0.66) | CYP4F2CYP4A11HSP90AB1ALDH1A1GAA | |
| SCHEMBL5546570 | 0.83 | CYP4F2 (0.66) | CYP4F2CYP4A11HSP90AB1ALDH1A1GAA | |
| SCHEMBL28063710 | 0.82 | CYP4F2 (0.59) | CYP4F2CYP4A11HSP90AB1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116731677-B | Foam dust settling agent for mines and preparation method thereof | 燕京装备制造有限公司 | 2026-02-27 | — | — | CN | claimed |
| CN-116731677-A | Foam dust settling agent for mines and preparation method thereof | 燕京装备制造有限公司 | 2023-09-12 | — | — | CN | claimed |
| CN-116731677-B | Foam dust settling agent for mines and preparation method thereof | 燕京装备制造有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | MERCK SHARP & DOHME LLC (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250127904-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | ADAXION THERAPEUTICS, INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2025076427-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20250109106-A1 | Synthetic intermediates and improved processes for preparing ROCk inhibitors | ALCON INC. (CH) | 2025-04-03 | — | — | US | disclosed |
| EP-3845276-B1 | BETA-AMINO ACID DERIVATIVE, KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND USE OF THE SAME | IND TECH RES INST (TW) | 2025-01-29 | — | — | EP | disclosed |
| US-20240383893-A1 | Hydroxamic Acid Compound Having ENPP1 Inhibitory Activity and Use Thereof | HAIHE BIOPHARMA CO., LTD. (CN) | 2024-11-21 | — | — | US | disclosed |
| EP-4463439-A1 | SYNTHETIC INTERMEDIATES AND IMPROVED PROCESSES FOR PREPARING ROCK INHIBITORS | Alcon Inc. (CH) | 2024-11-20 | — | — | EP | disclosed |
| EP-4400493-A1 | HYDROXAMIC ACID COMPOUND HAVING ENPP1 INHIBITORY ACTIVITY AND USE THEREOF | Haihe Biopharma Co., Ltd. (CN) | 2024-07-17 | — | — | EP | disclosed |
| EP-0690859-A1 | BENZYLIMIDAZOPYRIDINE DERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5395849-A | Hybrid antitumor compounds containing a cyclic enediyne and a DNA-binder | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-03-07 | — | — | US | disclosed |
| WO-1994020499-A1 | BENZYLIMIDAZOPYRIDINE DERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1994-09-15 | — | — | WO | disclosed |
| WO-1994020498-A1 | BENZYLIMIDAZOPYRIDINE DERIVATIVE AS ANGIOTENSIN II RECEPTOR ANTAGONIST | PFIZER INC. (US) | 1994-09-15 | — | — | WO | disclosed |
| US-5300668-A | Certain esters of 1-(4-X-methylphenyl)cyclopent-3-ene-1-carboxylic acid, wherein X is a trialkylsilyloxy, bromo or hydroxy group, as intermediates | PFIZER INC. (US) | 1994-04-05 | — | — | US | disclosed |
| US-5149462-A | Used as ferroelectric liquid crystal | MITSUBISHI RAYON COMPANY LTD. (JP) | 1992-09-22 | — | — | US | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| EP-0409066-A2 | Optically active compound for liquid crystal and its use | MITSUBISHI RAYON COMPANY, LTD. (JP) | 1991-01-23 | — | — | EP | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127904-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | SIGLEC7, SIGLEC9, SELPLG | CYP4F2 1606/4885CYP4A11 3099/4885HSP90AB1 3381/4885 |
| US-20250109106-A1 | Synthetic intermediates and improved processes for preparing ROCk inhibitors | ROCK1, ROCK2, RHOA | CYP4F2 3094/4885CYP4A11 405/4885HSP90AB1 2736/4885 |
| US-20240383893-A1 | Hydroxamic Acid Compound Having ENPP1 Inhibitory Activity and Use Thereof | ENPP1, ENPP2, ENPP3 | CYP4F2 4206/4885CYP4A11 3536/4885HSP90AB1 233/4885 |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | IL4I1, IL4, IL2 | CYP4F2 243/4885CYP4A11 75/4885HSP90AB1 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.